The two companies which develop medicines to improve vision have merged to prepare for a commercial launch of its drug that treats presbyopia.
British clinical stage biopharmaceutical company Tenpoint Therapeutics has completed its merger with Seattle-based Visus Therapeutics, a clinical stage company developing medicines to improve vision, to develop therapies to rejuvenate vision in the ageing eye.
The firm’s pipeline is focused on three treatments.
First and foremost, it is based on Brimochol, a once-a-day presbyopia-correcting eye drop. A combination of carbachol, a potent miotic, and brimonidine, the drug is an alpha2-agonist that is based on the vasoconstrictive properties of brimonidine, which helps reduce ocular redness and offers a potentially superior treatment for presbyopia.
The company said that Brimochol is on track for a new drug application (NDA) in the first half of next year.
Tenpoint Therapeutics is also working on TPT-161, a novel small molecule designed to reverse cataract formation in ageing adults, and TPT-005, a cell therapy targeting retinal pigment epithelium (RPE) cell replacement for geographic atrophy.
To support the continued development of these programs, Tenpoint said that it intends to embark on a crossover financing round with participation from syndicate members including AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Qiming Venture Partners USA, and Sofinnova Partners to fund the completion of clinical studies for Brimochol, preparations for a commercial launch in the first half of 2026, and the launch of the drug into the US market.
As part of the leadership transition, Henric Bjarke has been appointed chief executive of the newly merged company. Most recently, he was chief executive of Basel-based ACM Biosciences.
